Administration Timing Is the Best Clinical Outcome Predictor for Adalimumab Administration in Crohn's Disease

Biological intervention for Crohn's Disease (CDs) patients, mainly using anti-TNF antibodies, is often an efficient therapeutic solution. Nonetheless, data defining the administration timing to maximize the chances of clinical remission are lacking. The objective of this “real-life” retrospecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Mastronardi, Mauro, Curlo, Margherita, Cavalcanti, Elisabetta, Burattini, Osvaldo, Cuppone, Renato, Tauro, Romina, De Santis, Stefania, Serino, Grazia, Pesole, Pasqua Letizia, Stasi, Elisa, Caruso, Maria Lucia, Donghia, Rossella, Guerra, Vito, Giorgio, Pietro, Chieppa, Marcello
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6838026/
https://www.ncbi.nlm.nih.gov/pubmed/31737635
http://dx.doi.org/10.3389/fmed.2019.00234

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6838026/
https://www.ncbi.nlm.nih.gov/pubmed/31737635
http://dx.doi.org/10.3389/fmed.2019.00234

Ejemplares similares